TOKYO, April 30, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued an Investor Update regarding anti-cancer agent/ALK inhibitor Alecensa® (alectinib). The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended to approve Alecensa monotherapy as adjuvant treatment following complete tumor resection for adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer at high risk of recurrence*.*Stage IB (tumours ≥ 4 cm) - IIIA non-small cell lung cancer (UICC/AJCC 7th edition).

东京，2024年4月30日——Chugai Pharmaceutical Co.，Ltd.（东京：4519）宣布，罗氏发布了关于抗癌剂/ALK抑制剂Alecensa®（alectinib）的投资者更新。欧洲药品管理局（EMA）人类使用药品委员会（CHMP）建议批准Alecensa单一疗法作为成人间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌患者完全肿瘤切除后的辅助治疗复发风险高**IB期（肿瘤≥4 cm）-IIIA期非小细胞肺癌（UICC/AJCC第7版）。

CHMP recommends EU approval of Roche’s Alecensa as the first adjuvant treatment for resected ALK-positive early-stage lung cancerhttps://www.roche.com/investors/updates/inv-update-2024-04-26

CHMP建议欧盟批准罗氏Alecensa作为切除ALK阳性早期肺ca的第一种辅助治疗ncerhttps://www.roche.com/investors/updates/inv-update-2024-04-26